Page 426 - Read Online

Page 22 of 22 Droste et al. J Cancer Metastasis Treat 2023;9:2 https://dx.doi.org/10.20517/2394-4722.2022.94

132. Xu B, Zhang Q, Hu X, et al. Abstract GS1-06: a randomized control phase III trial of entinostat, a once weekly, class I selective
histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer.
Cancer Res 2022;82:GS1-06. DOI
133. Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or
without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing
on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013;31:2128-35. DOI PubMed PMC
134. Lee J, Lim B, Pearson T, Tripathy D, Ordentlich P, Ueno N. Abstract P5-21-15: the synergistic antitumor activity of entinostat (MS-
275) in combination with palbociclib (PD 0332991) in estrogen receptor-positive and triple-negative breast cancer. Cancer Res
2018;78:P5-21. DOI
135. Finn RS, Boer K, Bondarenko I, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with
letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast
Cancer Res Treat 2020;183:419-28. DOI PubMed PMC
136. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of
hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3):
final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425-39. DOI PubMed
137. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-
advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35:2875-84. DOI PubMed
138. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human
epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018;36:2465-72. DOI
PubMed
139. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human
epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated
overall survival. Ann Oncol 2021;32:1015-24. DOI
140. Rugo HS, Huober J, García-Sáenz JA, et al. Management of abemaciclib-associated adverse events in patients with hormone
receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and
MONARCH 3. Oncologist 2021;26:e53-65. DOI
141. Turner NC, Jhaveri KL, Bardia A, et al. persevERA breast cancer (BC): phase III study evaluating the efficacy and safety of
giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative
locally advanced or metastatic BC (ER+/HER2- LA/mBC). JCO 2021;39:TPS1103. DOI
142. Im S, Hamilton EP, Llombart Cussac A, et al. SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib,
versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously
received systemic treatment for advanced disease. JCO 2021;39:TPS1101. DOI